ניקורט קוויק מיסט ספריי 1 מג
j-c health care ltd - nicotine - nicotine 13.6 mg/ml - nicotine
ניקורט מנטה 4 מ"ג
j-c health care ltd - nicotine 4 mg - chewing gum - nicotine - for the relief of nicotine withdrawal symptoms as an aid to smoking cessation in adults over 18 years of age. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a program to reduce smoking prior to stopping completely.
ניקורט מנטה 2 מ"ג
j-c health care ltd - nicotine 2 mg - chewing gum - nicotine - for the relief of nicotine withdrawal symptoms as an aid to smoking cessation in adults over 18 years of age. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a program to reduce smoking prior to stopping completely.
ניקורט
j-c health care ltd - nicotine 10 mg - inhaler - nicotine - for the relief of nicotine withdrawal symptoms as an aid to smoking cessation in adults over 18 years of age. in smokers currently unable or not ready to stop smoking abruptly, the inhaler may also be used as part of a program to reduce smoking prior to stopping completely.
בייביזים טיפות
sam-on ltd - nicotinic acid; pepsin; sodium glycerophosphate - טיפות - pepsin 0.6 %w/v; nicotinic acid 0.2 %w/v; sodium glycerophosphate 0.8 %w/v - pepsin and acid preparations - pepsin and acid preparations - treatment of constipation and flatulence.
ניקוטינל tts 10
nutrition consumer health - nicotine 17.5 mg - patches - nicotine - aid to smoking cessation.
ניקוטינל tts 20
nutrition consumer health - nicotine 35 mg - patches - drugs used in nicotine dependence - aid to smoking cessation.
ניאספן 500 מ"ג טבליות מצופות בשחרור ממושך
abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n
ניאספן 750 מ"ג טבליות מצופות בשחרור ממושך
abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n
ניאספן 1000 מ"ג טבליות מצופות בשחרור ממושך
abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n